Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug1086	Hydroxychloroquine Wiki	0.10
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (5)

---

	Name (Synonyms)	Correlation
D055371	Acute Lung Injury NIH	0.10
D012127	Respiratory Distress Syndrome, Newborn NIH	0.10
D012128	Respiratory Distress Syndrome, Adult NIH	0.09
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine

Measure: Incidence of COVID-19 cases after two-doses immunization schedule

Time: Two weeks after second dose up to one year after first dose

---

Description: Frequency of adverse reaction in the seven days following each immunization per age group

Measure: Frequency of adverse events up to seven days after immunization

Time: Seven days after each immunization

---

Secondary Outcomes

Description: Number of virologically-confirmed symptomatic COVID-19 two weeks after first dose of vaccine

Measure: Incidence of COVID-19 cases after 14-days of first immunization

Time: Two weeks after first dose up to one year after first dose

---

Description: Number of virologically-confirmed symptomatic COVID-19 two weeks after last dose of vaccine, regardless the vaccination schedule was completed

Measure: Incidence of COVID-19 cases after 14-days of last immunization

Time: Two weeks after last dose uup to one year after first dose

---

Description: Number of virologically-confirmed and or serologically-confirmed SARS-CoV-2 infections two weeks after first dose of vaccine

Measure: Combined incidence of SARS-CoV-2 infection

Time: Two weeks after second dose up to one year after first dose

---

Description: Frequency of adverse reaction in the 28 days following each immunization per age gropu

Measure: Frequency of adverse events up to 28 days after immunization

Time: 28 days after each immunization

---

Description: Number of virologically-confirmed severe COVID-19 cases after receiving, at least, one dose of the vaccine

Measure: Incidence of severe COVID-19 cases

Time: From first vaccination up to one year after first dose

---

Description: Number of seroconversion responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants

Measure: Seroconversion rate

Time: Two weeks afer each vaccination

---

Description: Number of cell-mediated immune response against SARS-CoV-2 in the week two and four after the second vaccination per age group in a subset of participants

Measure: Cell-mediated immune profile

Time: Two and four weeks afer each vaccination

---